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INTRODUCTION
Since the gut is the largest lymphoid tissue in the
human body and has specific immunogenicity (1),
graft rejection is the most important threat to suc-
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Abstract : We previously reported that the combined treatment of perioperative admin-
istration of donor splenocytes via the recipient’s portal vein (DSPV) and a short-course
Tacrolimus significantly prolonged the survival of fully allogenic grafts in rat small bowel
transplantation (SBTX). In the present study we examined whether this effect depended
on the quantity of the administered alloantigens in DSPV. In addition, we examined the
expression of the surface antigen on T cells of the splenocytes and the induced toleragenic
factor, according to the tolerant recipients which in our previous report had shown the pro-
longation of allogenic transplant small bowel graft survival by the combined treatment
of DSPV (1×108 donor splenocytes) and a short-course Tacrolimus. Donor splenocytes were
prepared from Brown-Norway (BN (RT1n)) rat spleens for Lewis (LEW (RT1l)) recipients.
The recipients (n=10), treated with a short course of Tacrolimus (0.5mg/kg, 0 to 3 days
postoperatively) only showed graft rejection with an average of 6.3±1.0 days postoperatively.
However, the combined treatment, consisting of DSPV of 1×108 donor splenocytes and a
short course Tacrolimus significantly prolonged graft survival to 12.7±2.1 days (n=12,
P<0.01). DSPV of less than 1×108 donor splenocytes (5×107 cells and 2.5×107) could not prolong
the graft or animal survival under a short-course Tacrolimus treatment. In the tolerant
recipients, the CD4 and CD8 percentages of splenocytes were not significantly different from
those of control rats or recipients that were treated with short-course Tacrolimus alone.
Neverthless, the percentage of Tcr-αβ＋ cells expressing IL-2 receptor (R) was significant-
ly lower than in either control rats or the recipients with short-course Tacrolimus. In the
suppression assay to one-way mixed lymphocyte response, a toleragenic factor was sug-
gested to the present in the serum of the tolerant recipients. In the present study, it was
suggested that the effects of the combined treatment of DSPV and short-course Tacrolimus
for the prolongation of graft survival in the rat allogenic SBTX should depended on the quan-
tity of the antigens administered into the portal vein. The beneficial effects of this treat-
ment were reflected in the suppression of IL-2R on the recipient’s splenocytes, and tolerogenic
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cessful small bowel transplantation (SBTX) (2). Pow-
erful immunosuppressive agents, such as Tacrolimus,
have recently been exploited, and successful cases
of SBTX have markedly increased in the recent years
(3). However, complete prevention of graft rejec-
tion still remains an unresolved problem even during
the early postoperative period, and the long prolon-
gation of graft survival has not been achieved using
Tacrolimus alone. Especially in the early period after
SBTX, other immunosuppressive agents such as ster-
oid, cyclophosphamide and prostaglandin are addi-
tionally administered in practical SBTX cases (4).
These aggressive immunosuppressive treatments
damage the host’s immune systemwhichmight provoke
the severe infectious diseases, such as cytomegalo
virus infection (5).
In contrast to the progression of the chemical
immunosuppressive agents, various investigators have
studied the possibility of inducing a donor-specific
tolerance using biological methods (6). Many authors
have studied the administration of donor-specific
allo-antigens via the portal vein of the recipient in
experimental organ transplantations (6-8), and docu-
mented the beneficial effects for regulating the graft
rejection. On the basis of these studies, we previ-
ously examined the effects of the combined treatment
of perioperative administration of donor splenocytes via
the portal vein (DSPV) and short-course Tacrolimus
for the prolongation of allo-graft rejection in the rat
fully allogenic SBTX. In brief, the perioperative ad-
ministration of 1×108 Brown-Norway (BN (RT1n))
rats splenocytes into the systemic circulation caused
fatal graft-versus-host disease (GVHD) in Lewis (LEW
(RT1l)) recipients evenwhen short-course Tacrolimus
was combined. Without treatment, every allograft was
rejected and the recipients died during the early
postoperative days due to peritonitis caused by se-
vere graft rejection. DSPV only caused fatal GVHD and
the graft survival was not prolonged. A short -course
Tacrolimus treatment (0.5 mg/kg BW, 0 day to 3
day postoperatively) prolonged recipient survival, but,
graft survival was not prolonged. The combined treat-
ment of DSPV and a short-course of Tacrolimus sig-
nificantly prolonged both graft and recipient surviv-
al. However, all tolerant recipients that attained pro-
longation of transplant graft survival showed some
signs of mild GVHD. The beneficial effects on the
prolongation of allograft survival were confirmed to
be donor specific because the perioperative admin-
istration of the third-party WKA rats splenocytes
into the recipient’s portal vein could not prolong
the BN allograft survival. In vitro, donor-specific
down-regulation of one-way mixed lymphocyte re-
sponse (MLR) was also examined in tolerant recipi-
ents. Perioperative administration of the donor anti-
gens via the systemic vein was very dangerous
because it often induced fatal GVHD in the SBTX
recipients (2). Grant et al. previously suggested that
GVHD after SBTX damages host lymphoid tissues,
producing profound immunosuppression and creating
a risk of infectious complications (9). Several authors
have also reported that the risk of GVHD after SBTX
depends on the amount of administered alloantigens
(10, 11). Therefore, in the present study, we inves-
tigated the optimal dose of splenocytes in order to
assess the appropriate quantity of donor specific anti-
gens for the effective and safe treatment for DSPV.
We also examined the T cell surface antigens and
the tolerogenic factors in the tolerant recipients to




Inbred male BN (RT1n) and LEW (RT1l) rats were
obtained from the Seiwa experimental animal farm
(Fukuoka, Japan). The animals were bred under
pathogen-free conditions and were used for experi-
ments at a body weight of 200-300 g.
Intestinal transplantation
Operative procedures were performed under ether
anesthesia. The small intestine was transplanted in
the form of a Thiry-Vella fistula as described by
Kobayashi et al. (12). In brief, after an overnight
fast, a 10 cm segment of the proximal jejunum was
harvested from the donor on a vascular pedicle that
included the superior mesenteric artery and the por-
tal vein. The donor was systemically anticoagulated
with 200 U of heparin given intravenously immedi-
ately before graft removal. After excision, the intes-
tinal lumen was flushed, using 10 ml of Ringer’s lac-
tate. The donor mesenteric artery and the portal
vein were anastomosed to the recipient left renal
artery and vein, using a cuff technique. Both ends
of the graft were exteriorized as stomata, isolating
the segment from the recipient native gastrointes-
tinal tract.
Immunosuppressive agents
Tacrolimus, supplied in powder form by the Fujisawa
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Pharmaceutical Company (Osaka, Japan), was di-
luted in normal saline and injected intramuscularly
at a dose of 0.5 mg/kg body weight/ day from the
day of surgery until the third postoperative day (POD).
The properties and immunosuppressive activity of
this drug have been previously reported (13, 14).
Administration of donor splenocytes via the portal
vein (DSPV)
Following the experimental protocols, 1×108 million,
5×107 and 2.5×107 native splenocytes from BN rats
were injected perioperatively through the recipient’s
portal vein, using a 27-gauge needle. Cell viability as-
sessed by the trypan blue exclusion test was always
greater than 95%.
Experimental groups
The protocol included five treatment groups as fol-
lows : group A (n=10) ; Recipients given a short-course
Tacrolimus treatment (intramuscular doses of 0.5
mg/kg body weight/ day were injected intramusculary
on the day of operation and postoperative days 1-3) ;
group B (n=12) ; recipients given DSPV (1×108) and
a short-course Tacrolimus treatment ; group C (n=
10) ; recipients given DSPV (5×107) and a short-course
Tacrolimus treatment ; and Group D (n=8) ; recipients
given DSPV (2.5×107) and a short-course Tacrolimus
treatment. The details of the findings of the two groups,
A and B have been described previously (2).
Postoperative monitoring
After the small bowel transplantation, all rats re-
ceived standard rat chow and water ad libitum. The
rats that died within two days were considered to
be technical failures and excluded from this analy-
sis. Autopsies were performed to confirm the cause
of death. Graft rejection was evaluated by the clini-
cal signs, previously described by Zhang et al, of pro-
gressive stomal ischemia, stomal closure and an
abdominal mass (15). The severity of GVHD was
estimated by clinical grading, as previously described
by Saat et al . (16) : grade I (mild), light redness of
ears, snout, and paws ; grade II (moderate), mod-
erate redness of ears, snout, and paws, with slight
hair loss and diarrhea;and grade III (fatal), severe
redness of ears, snout and paws, with alopecia, gen-
eralized dermatitis, and profuse diarrhea. In the
present study, signs of grade II (moderate) and grade
III (fatal) GVHD were not detected in any animal.
Mixed lymphocyte culture and suppressor assay
Both splenocytes and serum were obtained from
the SBTX recipients (n=5) with DSPV (1×108) and
a short-course Tacrolimus treatment on the seventh
postoperative day. Various cell numbers (1×105,
5×104, 2.5×104) of these SBTX recipient’s splenocytes
were added to the micro-titer culture plate wells of
mixed lymphocyte culture (MLC) in which 5×105
native responder LEW splenocytes responded toward
5×105 mitomysin C treated stimulator splenocytes
of BN or third-party WKA rats. The SBTX recipient
sera were diluted, and then added into the wells of
MLC at various concentrations (10%, 5%, 2.5%/200
µl total volume). After five days incubation at 37℃
in a humidified atmosphere of 5% CO2, in air, 0.5µCi
of [3H]-methylthymidine (N E N, Boston, MA) was
added to each well. After incubating for another 18
hrs, the mixed lymphocyte culture proliferative re-
sponse (MLR) was determined by measuring incor-
poration of [3H]-methylthymidine by direct β counting
(Packard Instrument B.V. Chemical Operations, The
Netherlands). The results were expressed as themean
cpm of triplicate cultures. The percentage of sup-
pression was calculated using the formula :
% suppression = (1-experimental cpm/positive con-
trol cpm)×100. Positive control MLC ; 5×105 native
responder LEW splenocytes responded toward 5×105
mitomysin C treated stimulator splenocytes of BN
or third-party WKA rats. This positive control MLC
recieved neither tolerant SBTX recipients’ splenocytes
nor their serum in contrast to the experimental MLC
which received either tolerant SBTX recipients’
splenocytes or their serum.
Antibodies
Anti-rat CD4 mAb, W3/25, anti-rat CD8, mAb,
OX8, and anti-rat IL-2R, mAb, OX39 were from
Dr. M. Miyasaka, Tokyo Metropolitan Institute for
Medical Science, Anti-rat TCR-αβ mAb-producing
R73, hybridoma cell line was a gift fromDr. T. Hunig
(University of Wurzberg, Germany).
Flow-cytometric analysis
Splenocytes were stained with combinations of
FITC-conjugated mAb and biotin-conjugated mAb,
followed by staining with PE-streptavidin. Analyses
were performed with a FACScan and Consort 30
software (Becton Dickinson, Mountain View, CA).
Dead cells were gated out using forward and side
light intensities.
Statistical analysis
All comparisons were made using the Student’s
t test. Differences in values were considered signifi-
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cant at P<0.05.
RESULTS
Observations of animals transplanted with intesti-
nal allografts
After transplantation, recipients were monitored
for rejection and GVHD (Table 1). All recipients
treated with Tacrolimus alone (group A) showed
graft rejection signs at 6.3±1.0 POD. Seven of 10
animals died from rejection with peritonitis within
24 POD. One animal died from an obstructed ileus
due to the small bowel adhesion to the rejected graft.
Two animals survived over 70 POD despite signs of
graft rejection. In recipients treated with both DSPV
(1×108) and Tacrolimus (group B), graft survival was
significantly prolonged (12.7±2.1 days, P<0.01) com-
pared with group A. In recipients treated with DSPV
(5×107) and Tacrolimus (group C), graft survival was
not prolonged (6.9±0.8 days) compared with group
A. The period of animal survival was not longer than
that of the recipients for short-course Tacrolimus
alone : six of ten recipients died between 9 days and
33 days postoperatively. Four recipients survived
for more than 70 days, even though signs of the graft
rejection were confirmed within 7 days postoperative.
Of note, these long surviving animals also showed
signs of mild GVHD. The recipients treated with the
lower dose DSPV (2.5×107) and short-course Tacrolimus
(group D) also did not show prolonged the graft
survival (6.3±0.7 days) or recipient survival : seven
of 8 recipients died between 7 and 62 days postoperative.
Only one recipient survived for more than 70 days
despite of the evident clinical signs of mild GVHD.
Antigen-specific suppressor factor in the serum from
the torelant recipients
The sera obtained from the SBTX recipients with
DSPV (1×108) and short-course Tacrolimus treat-
ment at the seventh postoperative day, suppressed
mixed lymphocyte culture proliferative response
(MLR) of LEW responder cells towards BN, but not
WKA stimulator cells, depending on the serum con-
centrations of these SBTX recipients in mixed lympho-
cyte culture wells ; Inhibition rate : 10% serum (46.7±
6.7% vs 2.5±10.3% ; P<0.01), 5% serum (21.0±4.9%
vs 1.5±9.1% ; P<0.01) and 2.5% serum (1.2±4.0% vs
4.4±12.2% ; NS), respectively. The same recipient
sera, treated at 56℃ for 30 minutes, also suppressed
MLR, depending on the concentration ; Inhibition
rate : 10% serum (54.8±11.0% vs -0.0±8.6% ; P<0.01),
5% serum (16.2±4.0% vs -0.5±10.5% ; P<0.05) and
2.5% serum (-0.3±4.7% vs -0.5±9.8% ; NS), respec-
tively (Fig. 1).
Failure to detect suppressor activity in splenocytes
from tolerant recipients
1×105, 5×104, and 2.5×104 of splenocytes, obtained
from the recipients treated with DSPV (1×108) and
short-course Tacrolimus, could not suppressMLR of
LEW responder cells toward either BN or third-party
WKA stimulator cells ; Inhibition rate : 1×105 (-5.00±
2.68% vs 0.06±3.01% ; NS), 5×104 (-0.74±5.21% vs
1.86±3.83% ; NS), 2.5×104 (-2.76±5.99% vs 1.47±
5.43% ; NS), respectively (Fig. 2).
Flow-cytometric analysis
Fig. 3 shows the expression of W3/25＋ (CD4＋)
































Underlining indicates mild GVHD in all experimental groups. a indicates death from volvulus. The results of group
A and B have been already described in our previous report (2). All animals of these four experimental groups
were treated with Tacrolimus at a dose of 0.5mg/kg body weight/ day from the day of surgery until the third
postoperative day (POD).
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Fig. 1. Suppressor assay of mixed lymphocyte
culture proliferative response by the tolerant SBTX
recipient’s serum. The sera were obtained from
the five SBTX recipients that were treated with
short-course Tacrolimus and DSPV (1×108) on
7 POD. The serum was diluted and added into
mixed lymphocyte culture wells, in which 5×105
native LEW splenocytes responded toward 5×105
mitomysin C treated stimulator BN (■) or WKA
(●) splenocytes at various concentrations (10%,
5%, 2.5%/200µl total volume). Results are presented
as % suppression, calculated as described in Ma-
terials and Methods. The minimal spontaneous
(LEW-to-LEW) cpm was 67.
Fig. 2. Suppressor assay ofmixed lympho-
cyte culture proliferative response by the
tolerant SBTX recipient’s splenocytes. Vari-
ous number of splenocytes (1×105, 5×
104, 2.5×104) obtained from the SBTX
recipients with short-course Tacrolimus
treatment and DSPV (1×108) on 7 POD,
were added into mixed lymphocyte cul-
ture wells, in which 5×105 native LEW
splenocytes responded toward 5×105
mitomysin C treated stimulator BN (■)
or WKA (●). Results are presented as
% suppression, calculated as described in
Materials andMethods. Theminimal spon-
taneous (LEW-to-LEW) cpm was 69.
Fig. 3. Representative flowcytometric analysis of splenocytes from native rats(left), the recipient rats treated with short-course
Tacrolimus only (middle), and the recipient rats treated with short-course Tacrolimus and DSPV (right). Cells prepared on 7 POD
were stained with FITC-anti-CD 8 and biotin-anti-CD 4, followed by staining with PE-streptavidin. Numbers indicate percentage of each
population (mean±SD). Symbol ＊ means that in recipients treated with short-course Tacrolimus alone, the percentage of CD4＋ T
cells population decreased significantly (P<0.05) compared with that of control rats.
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and OX8＋ (CD8＋) cells in splenocytes from control
and allografted animals at 7 POD (each experimen-
tal number of animals was five). The mean ratio of
CD4＋ cells was 47.8±5.0% in control LEW rats ; in
recipients treated with short-course Tacrolimus alone,
the percentage of this population decreased signifi-
cantly (P<0.05) to 33.6±1.2%. In the tolerant recipients
treated with DSPV (1×108 cells) and short-course
Tacrolimus, the mean ratio of CD4＋ cells was 37.5±
7.5%, which was not significantly different from the
other two groups. The mean ratio of CD8＋ cells in
splenocytes showed no significant difference between
control rats (20.0±3.4%), recipients of Tacrolimus
alone (13.5±7.5%), and recipients treated with DSPV
(1×108 cells) and short-course Tacrolimus (20.0±
2.7%). Fig. 4 shows the expression of IL-2R on TCR-αβ＋
splenocytes. The proportion of IL-2R＋ cells in TCR-αβ＋
splenocytes from recipients of short-course Tacrolimus
alone was 25.5±7.6%, which was higher than that
for control rats (5.1±3.6%). The IL-2R positive T cells
of recipients treated with the combination of DSPV
(1×108 cells) and short-course Tacrolimus, was 1.7±0.5 % ;
significantly (P<0.05) lower than that of the recipients
which were treated with short-course Tacrolimus alone
but no significantly different from that of control
rats.
DISCUSSION
The phenomena in which the intra-portal and oral
administration of antigen induce immune tolerance
have been known as the Chase-Surzberger effect
(17). On the basis of this advantage for inducing
immunological tolerance, many studies have exam-
ined the effects of administration of donor-specific
antigens into the portal vein (DSPV) for protection
against graft rejection in the experimental organ
transplantations and reported the beneficial effects.
Previous studies, according to DSPV, have proposed
several possible mechanisms for the induction of
tolerance : the inability of Kupffer cells to present
the antigen (18) ; the preferential generation of T
suppressor cells due to the slow release of antigen
by the liver (19);the presence of a factor in the serum
that mediates tolerance (20) ; and selective activa-
tion of TH1/Th2 cells (21). We previously studied
the effects of DSPV in SBTX, using fully allogenic rat
strains (BN-to-LEW), and demonstrated that DSPV
has the advantage of prolonging the BN small bowel
graft survival in the LEW recipient under short-course
Tacrolimus treatment. However, the findings gave
rise to another important problem ; GVHD, which
might be a threat to the successful treatment for
SBTX. Indeed, short-course Tacrolimus proved to
be useful for ameriolating lethal GVHD, which was
induced in recipients treated with DSPV by 1×108
splenocytes alone. However, all tolerant recipients
showed signs of mild GVHD. It was suggested that
this mild GVHD in tolerant recipients was caused
by the splenocytes, which entered the recipient’s
systemic circulation without liver trapping (2). Ac-
cording to the tolerance of organ transplantation,
Starzl et al. postulated a two-way paradigm, i.e. a
Fig. 4. IL-2R expression on TcR-α β＋ splenocytes from native rats (left), the recipient rats treated with short-course Tacrolimus alone
(middle), and the recipient rats treated with short-course Tacrolimus and DSPV(right) on 7 POD. Splenocytes were stained with
FITC-anti-TcR-α β＋ and biotin-anti-IL-2 R, followed by staining with PE-streptavidin. Results represent single histogram pattern of
gated TcR-αβ＋ cells. Numbers indicate percentage of IL-2R＋ cells. Symbol ＊ means that IL-2R relative cell number was significantly
higher than that of control rats (P<0.05). Symbol ※ means that IL-2R positive T cells of recipients treated with the combined treatment
of DSPV (1×108) and short-course Tacrolimus was significantly (P<0.05) lower than that of the recipients treated with short-course
Tacrolimus alone and showed no significant difference from that in control rats.
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balance of opposing immunologic forces between
rejection and GVHD in organ transplantation (22).
Following SBTX, there is a large bi-directional trans-
fer of lymphoid cells between the graft and the recipient
(23). Murase et al . described that the incidence of
lethal GVHD depends on either the dose or qual-
ity of the passenger leukocytes, and reported that
in the transplantation of intestine, spleen or lymphocytes
enriched with T cells, 5%～7% of the donor-derived
cells were found in the recipient’s organs, and that
the proportion of T cells was higher than that of other
lineages of donor cells. In a chimeric recipient’s tis-
sues, over-representation of donor T cells was asso-
ciated with GVHD (24). Kenick et al. have suggested
that the induction of tolerance following DSPV might
depend on the quantity of allogenic cells trapped by
the liver (25). Kamei et al. described that the initial
effective uptake of alloantigens by Kupffer cells ap-
peared to be essential for their presentation of anti-
gen in the liver (26).
In the present study, we examined the optimum
dose of the donor splenocytes for DSPV. Yoshimura
et al . described that 2×108 splenocytes might give
rise to emboli, which could cause recipient death (27),
and therefore we determined that the 108 splenocytes
was the maximum dose for DSPV. DSPV of 5×107
and 2.5×107 splenocytes could not prolong graft sur-
vival. These findings strongly suggest that the in-
duction of tolerance after DSPVmight depend on the
quantities of allogenic cells trapped by the liver. Of
note, a lower quantity of splenocytes, even at a dose
of 2.5×107, was shown to have a risk of inducing
GVHD. In respect to this point, Kobayashi et al. re-
cently described that the major SBTX damages the
host lymphoid organ, especially thymic T cells, and
increases host sensitivity to GVHD (28). In the present
study, it is suggested that the signs of mild GVHD
provoked by a low dose of DSPVmight support their
finding.
Qian et al. described that the generation of serum
factor might be able to transfer alloantigen-specific
tolerance for DTH by DSPV in the murine system
(6). In the present study, suppressor activity was not
identified in splenocytes from tolerant recipients,
while antigen-specific suppressor factor(s) was
suggested in the serum of the tolerant recipients.
From these findings, it was suggested thatDSPVmight
produce suppressor factors, which could regulate the
graft rejection in SBTX.
We have already described that the beneficial effect
of DSPV in vitro was reflected in the donor specif-
ic downregulation of one-way MLR (2). According
to the surface antigens of tolerant recipient T cells,
the findings of the present study suggested that DSPV
could suppress T cell activity against donor-specific
antigens, because IL-2R is known to be expressed
on activated T lymphocytes (29). According to the
ratios of CD4＋/CD8＋ cells among splenocytes, there
was no significant difference between the tolerant
recipients and non-tolerant recipients. Recently, help-
er T cells have been divided into two groups, Th1
and Th2, according to their cytokine production (30).
IL-2, a Th1-derived cytokine, produced after T cell,
B cell stimulation during the amplification of immune
response, may provide the environment necessary for
anergy induction (31). Based on the non-responsiveness
(T cell tolerance or anergy) produced by adminis-
tration of alloantigens via the portal vein, Gorczynski
et al. described that presentation of multiple minor
cell surface antigens by hepatic antigen presenting
cells leads to anergy induction in IL-2 producing T
cells (Th1), and also that subsequent activation of
Th2 cells with further feedback inhibition of Th1
cells may play an important role in the long-term
allograft survival (21). In the present study, it was
suggested that donor-specific serum factor(s) might
suppress IL-2R expression on the splenocytes in the
tolerant recipients. Sullivan et al. recently reported
that the livermay regulate the rejection of vascularized
allografts (in particular small bowel and renal allografts)
due to the altered migration of lymphoid cells into
and out of the graft after portal drainage. They also
reported that the altered ratios of γ δTcR+/αβTcR+
cells, altered cytokine production (IL-2, INF-γ, IL-4,
IL-10), and/or other functional activities may play
key roles in determining successful engraftment (32).
Gorczynski et al . have recently reported that after
the portal venous drainage of small bowel graft, type-2
cytokine (IL-4, IL-10, TGFβ) producing γ δTcR+ cells
may play an important role in regulating graft re-
jection (33). In contrast, Starzl et al . reported that
microchimerism could be important for inducing
immunological tolerance in organ transplantations
(22), including SBTX. However, we did not study
chimerism in the present study. The detailed mecha-
nisms of the tolerance after DSPV still remain ob-
scure.
In conclusion, the effective advantages of combined
treatment of DSPV and short course Tacrolimus for
the prolongation of graft survival in rat SBTX de-
pended on the quantity of donor-specific antigens
administered via the recipient’s portal vein. In the
present study, the effects of the protection of the
SRTX allo-grafts might be reflected in the suppression
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of IL-2R expression on the recipient’s splenocytes.
Furthermore, the recipient’s serum factor(s), which
were induced in the tolerant SBTX recipients, might
play an important role in the protection of small bowel
allo-grafts.
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